Benzinga | May 4, 2021 09:08AM EDT

Editas Medicine Reports Will Present Preclinical Data Showing Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting May 10, 11

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held virtually May 11 -- 14, 2021.

Editas Medicine Scientist Heather MacLeod, Ph.D., will speak at the ASGCT Gene Editing Workshop. Her presentation, The Development of CRISPR Based Medicines for the Treatment of Ocular Diseases, will be part of ASGCT's pre-meeting program Moving Genome Editing to the Clinic: From Technology to Therapeutics. In addition, the Company is presenting preclinical data demonstrating therapeutically relevant levels of editing using a dual AAV CRISPR-Cas9 system as a therapeutic strategy for the treatment of retinitis pigmentosa 4 (RP4) on May 11.

Full details of the Editas Medicine presentations can be accessed on the ASGCT website at https://annualmeeting.asgct.org/abstracts.

Invited Talk:

Title: The Development of CRISPR Based Medicines for the Treatment of Ocular Diseases

Date and Time: Monday, May 10, 2021, 11:15 -- 11:40 a.m. ET

Session Title: Moving Genome Editing to the Clinic: from Technology to Therapeutics

Session Type: Pre-Meeting Workshop

Poster Presentation:

Title: Advances Toward a Dual AAV CRISPR-Cas9-based "Knockout and Replace" Strategy to Treat Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa

Date and Time: Tuesday, May 11, 2021, 8:00 -- 10:00 a.m. ET

Session Title: Neurologic Diseases

Research Collaboration Poster Presentation (Editas Medicine Author):

Title: AsCas12a Ultra Nuclease Facilitates the Rapid Generation of Therapeutic Cell Medicines

Date and Time: Tuesday, May 11, 2021, 8:00 -- 10:00 a.m. ET

Session Title: Gene Targeting and Gene Correction